CTOs on the Move

Civica Rx

www.civicarx.org

 
Civica Rx was created in late 2018 to secure the supply of important medicines hospitals use every day. As of Q2 2023, we have provided over 125 million units of essential medicines to hospitals, enough to help treat over 50 million patients. Recently, we announced we will manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin. Insulin is an exciting project as we are partnering with nearly every corner of the diabetes ecosystem to bring low-cost insulin to people living with diabetes at no more than $30 a vial and no more than $55 for ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.civicarx.org
  • 2912 Executive Parkway
    Lehi, UT USA 84043
  • Phone: 888.304.0120

Executives

Name Title Contact Details

Similar Companies

Taro Pharmaceuticals (HQ)

"Taro Pharmaceuticals U.S.A., Inc., and its divisions, subsidiaries and affiliates (collectively, ""Taro"") operate a variety of websites designed to provide you with services ranging from valuable health resources to corporate news and product information"

Zeno Health

Mumbais #1 Generic Medicine Pharmacy 100+ Stores | 200 Crore+ Savings Delivered | Trusted by over 15 Lakhs+ Customer

LiNA Medical

THE PLANNING SHOP International

THE PLANNING SHOP International is a Jamison, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RedPath Integrated Pathology, Inc

RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers.